pyrotinib: Clinical Trials

23 trials of pyrotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 5 not yet recruiting, 5 unknown, 4 active not recruiting. 23 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Recruiting 7, Not yet recruiting 5, Unknown 5, Active not recruiting 4, Completed 2
Phase 23Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
Fulvestrant, Pyrotinib, Dalpiciclib - Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer
Phase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2262026-11-012026-10-23
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
Docetaxel, Pyrotinib, Trastuzumab (Herceptin) - Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Phase 3RecruitingShanghai Jiao Tong University School of Medicine2202026-07-012026-09-01
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma
Phase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute902026-07-012026-06-17
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w, Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg/m² ivgtt d1 q3w, - Breast Cancer
Phase 3RecruitingFudan University5022025-02-122026-05-29
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
pyrotinib - HER2 Positive Breast Cancer, Pyrotinib Treatment
Phase 2 / Phase 3RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences9642024-04-302025-05-06
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel - Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Phase 3Active not recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University1602024-01-172026-10-27
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
disitamab vedotin, Pyrotinib, trastuzumab - HER2-positive Metastatic Breast Cancer, First-line Treatment
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University3122023-09-062024-02-26
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
pyrotinib - Breast Cancer Invasive
Phase 3RecruitingRenJi Hospital4882023-06-012025-11-18
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Pyrotinib, Trastuzumab, Paclitaxel - Breast Cancer
Phase 3Not yet recruitingFudan University8762023-05-062023-05-03
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
SHR-A1811, Pyrotinib in combination with Capecitabine. - HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.3812022-08-042025-08-22
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy - HER2-positive Breast Cancer, Metastatic Breast Cancer
Phase 3UnknownFudan University2402021-09-152022-04-26
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Pyrotinib, Trastuzumab - Breast Cancer
Phase 3Not yet recruitingShengjing Hospital4502021-08-012021-07-22
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Inetetamab, Rapamycin, Pyrotinib - Breast Cancer
Phase 3Not yet recruitingPeking Union Medical College2702021-02-022021-02-03
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer
Phase 3UnknownFirst Affiliated Hospital Xi'an Jiaotong University1202021-01-012022-06-23
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib - Breast Cancer
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University5162020-10-142020-11-30
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Pyrotinib, Docetaxel - Non-squamous NSCLC, HER2 Exon 20 Mutation
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.1512020-09-112025-12-19
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Pyrotinib, Epirubicin, Cyclophosphamide - Breast Cancer
Phase 2 / Phase 3Active not recruitingHebei Medical University Fourth Hospital1132020-03-012026-01-07
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
pyrotinib - Locally Advanced Breast Cancer
Phase 3RecruitingRenJi Hospital3162019-12-162025-09-11
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Pyrotinib, Placebo - Breast Cancer
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.21352019-07-122026-08-17
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Pyrotinib, Trastuzumab, Docetaxel, Placebo, Trastuzumab, Docetaxel - Metastatic Breast Cancer
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.5902019-04-222022-11-23

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Breast Neoplasms (12)  ·  Esophageal Squamous Cell Carcinoma (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (7)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4)  ·  Fudan University (3)  ·  RenJi Hospital (2)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)  ·  Hebei Medical University Fourth Hospital (1)  ·  Peking Union Medical College (1)  ·  Peking University Cancer Hospital & Institute (1)  ·  Shanghai Jiao Tong University School of Medicine (1)  ·  Shengjing Hospital (1)

Countries

China (21)  ·  Australia (1)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  United States (1)

Top investigators

Ying Wang (2)  ·  Cai-Gang Liu, MD (1)  ·  Chang Gong, Prof (1)  ·  Fei Ma, MD (1)  ·  Hongxia Wang, Chief physician (1)  ·  Jiani Wang, M.D. (1)  ·  Jin Yang, Doctor (1)  ·  Jinsong Lu (1)  ·  Wei Shi, MD,PhD (1)  ·  Wenjin Yin, M.D. (1)  ·  Zhimin Shao (1)

Results publications

PMID 33328035, PMID 33581774, PMID 36135045, PMID 36575513, PMID 37907210, PMID 39024777, PMID 41839514, PMID 42385760